Citations (23)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (9)
A. F. G. Cicero, M. Landolfo & C. Borghi. (2020) Are monotherapies still valuable to the treatment of hypertension?. Expert Opinion on Pharmacotherapy 21:13, pages 1523-1526.
Read now
Read now
Christina Antza, Stella Stabouli & Vasilios Kotsis. (2016) Combination therapy with lercanidipine and enalapril in the management of the hypertensive patient: an update of the evidence. Vascular Health and Risk Management 12, pages 443-451.
Read now
Read now
Ying Wu, Mengdan Xu, Hao Wang, Xin Xu, Shuiping Zhao, Mei Zhang, Huigen Jin, Jinchuan Yan, Bangning Wang, Jianbin Gong, Xiang Lu, Jianqiang Peng & Qiuyan Dai. (2015) Lercanidipine hydrochloride versus felodipine sustained-release for mild-to-moderate hypertension: a multi-center, randomized clinical trial. Current Medical Research and Opinion 31:1, pages 171-176.
Read now
Read now
Michel Burnier, Menno Pruijm & Gregoire Wuerzner. (2009) Treatment of essential hypertension with calcium channel blockers: what is the place of lercanidipine?. Expert Opinion on Drug Metabolism & Toxicology 5:8, pages 981-987.
Read now
Read now
Giuliano Tocci, Francesca Palano, Erika Pagannone, Diana Chin, Andrea Ferrucci & Massimo Volpe. (2009) Fixed-combination therapies in hypertension management: focus on enalapril/lercanidipine. Expert Review of Cardiovascular Therapy 7:2, pages 115-123.
Read now
Read now
Menno T Pruijm, Marc P Maillard & Michel Burnier. (2008) Patient adherence and the choice of antihypertensive drugs: focus on lercanidipine. Vascular Health and Risk Management 4:6, pages 1159-1166.
Read now
Read now
Michel Burnier & Urs E Gasser. (2007) Efficacy and tolerability of lercanidipine in patients with hypertension: results of a Phase IV study in general practice. Expert Opinion on Pharmacotherapy 8:14, pages 2215-2223.
Read now
Read now
C Venkata S Ram. (2006) Hypertension, possible vascular protection and lercanidipine. Expert Review of Cardiovascular Therapy 4:6, pages 783-788.
Read now
Read now
Claudio Borghi. (2005) Lercanidipine in Hypertension. Vascular Health and Risk Management 1:3, pages 173-182.
Read now
Read now
Articles from other publishers (14)
Ling Liang, Janice Y. Kung, Bradley Mitchelmore, Andrew Cave & Hoan Linh Banh. (2022) Comparative peripheral edema for dihydropyridines calcium channel blockers treatment: A systematic review and network meta‐analysis. The Journal of Clinical Hypertension 24:5, pages 536-554.
Crossref
Crossref
F. Fici, G. Seravalle, N. Koylan, I. Nalbantgil, N. Cagla, Y. Korkut, F. Quarti-Trevano, W. Makel & G. Grassi. (2017) Follow-up of Antihypertensive Therapy Improves Blood Pressure Control: Results of HYT (HYperTension survey) Follow-up. High Blood Pressure & Cardiovascular Prevention 24:3, pages 289-296.
Crossref
Crossref
M. Burnier, Y. Vuignier & G. Wuerzner. (2013) State-of-the-art treatment of hypertension: established and new drugs. European Heart Journal 35:9, pages 557-562.
Crossref
Crossref
Viktor Viktorovich Fomin & Sergey Valentinovich Moiseev. (2013) Sovershenstvovanie podkhodov k primeneniyu antagonistov kal'tsiya: fokus na lerkanidipin. CardioSomatics 4:3, pages 42-45.
Crossref
Crossref
A de la Sierra. (2009) Mitigation of calcium channel blocker-related oedema in hypertension by antagonists of the renin–angiotensin system. Journal of Human Hypertension 23:8, pages 503-511.
Crossref
Crossref
Kelly Makarounas-Kirchmann, Sophie Glover-Koudounas & Paolo Ferrari. (2009) Results of a meta-analysis comparing the tolerability of lercanidipine and other dihydropyridine calcium channel blockers. Clinical Therapeutics 31:8, pages 1652-1663.
Crossref
Crossref
Steven G. Chrysant. (2008) Proactive Compared With Passive Adverse Event Recognition: Calcium Channel Blocker-Associated Edema. The Journal of Clinical Hypertension 10:9, pages 716-722.
Crossref
Crossref
V. Barrios, C. Escobar, M. De La Figuera, J. Honorato, J. L. Llisterri, J. Segura & A. Calderón. (2008) High doses of lercanidipine are better tolerated than other dihydropyridines in hypertensive patients with metabolic syndrome: results from the TOLERANCE study. International Journal of Clinical Practice 62:5, pages 723-728.
Crossref
Crossref
Vivencio Barrios, Carlos Escobar, Mariano De La Figuera, Jose Luis Llisterri, Jesus Honorato, Julián Segura & Alberto Calderón. (2008) Tolerability of High Doses of Lercanidipine versus High Doses of Other Dihydropyridines in Daily Clinical Practice: The TOLERANCE Study. Cardiovascular Drug Reviews 26:1, pages 2-9.
Crossref
Crossref
J. A. Cramer, Á. Benedict, N. Muszbek, A. Keskinaslan & Z. M. Khan. (2007) The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: a review. International Journal of Clinical Practice 62:1, pages 76-87.
Crossref
Crossref
Cherylyn Beckey, Amber Lundy & Nahla Lutfi. (2016) Lercanidipine in the Treatment of Hypertension. Annals of Pharmacotherapy 41:3, pages 465-474.
Crossref
Crossref
Rahul Agrawal, Axel Marx & Hermann Haller. (2006) Efficacy and safety of lercanidipine versus hydrochlorothiazide as add-on to enalapril in diabetic populations with uncontrolled hypertension. Journal of Hypertension 24:1, pages 185-192.
Crossref
Crossref
G. M. Bronskaya, M. Moubarak Ali, O. L. Palkovsky & V. P. Vdovichenko. (2005) DIHYDROPIRIDINE CALCIUM ANTAGONISTS OF III GENERATION IN TREATMENT OF ARTERIAL HYPERTENSION. Health and Ecology Issues:4, pages 17-25.
Crossref
Crossref
Edoardo Casiglia, Alberto Mazza, Valérie Tikhonoff, Giancarlo Basso, Bortolo Martini, Roberta Scarpa & Achille Cesare Pessina. (2004) Therapeutic profile of manidipine and lercanidipine in hypertensive patients. Advances in Therapy 21:6, pages 357-369.
Crossref
Crossref